ImmunityBio, Inc. (IBRX)
NASDAQ: IBRX · Real-Time Price · USD
7.32
+0.07 (0.97%)
At close: Aug 6, 2026, 4:00 PM EDT
7.33
+0.01 (0.14%)
After-hours: Aug 6, 2026, 7:59 PM EDT
ImmunityBio Revenue
ImmunityBio had revenue of $51.24M in the quarter ending June 30, 2026, with 93.91% growth. This brings the company's revenue in the last twelve months to $165.79M, up 192.92% year-over-year. In the year 2025, ImmunityBio had annual revenue of $113.29M with 668.31% growth.
Revenue (ttm)
$165.79M
Revenue Growth
+192.92%
P/S Ratio
46.79
Revenue / Employee
$239,931
Employees
691
Market Cap
7.76B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 113.29M | 98.54M | 668.31% |
| Dec 31, 2024 | 14.75M | 14.12M | 2,270.58% |
| Dec 31, 2023 | 622.00K | 382.00K | 159.17% |
| Dec 31, 2022 | 240.00K | -694.00K | -74.30% |
| Dec 31, 2021 | 934.00K | 329.00K | 54.38% |
| Dec 31, 2020 | 605.00K | -1.60M | -72.52% |
| Dec 31, 2019 | 2.20M | 2.16M | 4,585.11% |
| Dec 31, 2018 | 47.00K | 2.00K | 4.44% |
| Dec 31, 2017 | 45.00K | 1,000.00 | 2.27% |
| Dec 31, 2016 | 44.00K | -192.00K | -81.36% |
| Dec 31, 2015 | 236.00K | -405.00K | -63.18% |
| Dec 31, 2014 | 641.00K | 41.00K | 6.83% |
| Dec 31, 2013 | 600.00K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| TG Therapeutics | 799.54M |
| Mirum Pharmaceuticals | 569.61M |
| Rhythm Pharmaceuticals | 217.17M |
| Protagonist Therapeutics | 74.06M |
| Kymera Therapeutics | 51.48M |
| Crinetics Pharmaceuticals | 42.16M |
| Praxis Precision Medicines | 7.46M |
IBRX News
- 2 days ago - ImmunityBio reports Q2 EPS (22c) vs. (10c) last year - TheFly
- 2 days ago - ImmunityBio Reports Record Q2 2026 Net Product Revenue of $50.7 Million, Up 92% Year-Over-Year; First-Half Revenue Up 121% to $94.8 Million - Business Wire
- 2 days ago - ImmunityBio Earnings release: Q2 2026 - Filings
- 2 days ago - ImmunityBio Quarterly report: Q2 2026 - Filings
- 8 days ago - ImmunityBio Receives United Arab Emirates (UAE) Marketing Authorization for ANKTIVA® Across BCG-Unresponsive Non-Muscle Invasive Bladder Cancer for CIS and Papillary Disease and Metastatic Non-Small Cell Lung Cancer - Business Wire
- 2 months ago - ImmunityBio Transcript: AGM 2026 - Transcripts
- 2 months ago - ImmunityBio Transcript: Jefferies Global Healthcare Conference 2026 - Transcripts
- 2 months ago - ImmunityBio Presents New Clinical and Comparative Data Across Lung and Bladder Cancer at ASCO 2026 - Business Wire